CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: June-29-12
Credit Expiration Date: June-29-13


Aaron B. Waxman, MD, PhD (moderator)
Associate Professor
Department of Medicine
Harvard Medical School
Pulmonary and Critical Care Medicine
Brigham and Women’s Hospital
Boston, MA

Murali Chakinala, MD, FCCP
Associate Professor of Medicine
Division of Pulmonary & Critical Care Medicine
Washington University School of Medicine
St. Louis, MO

Victor F. Tapson, MD
Professor of Pulmonary and Critical Care Medicine
Director, Pulmonary Vascular Disease Center
Duke University Medical Center
Durham, NC


Video Roundtable

Program Description

A rapid pace of development has led to new insight into diagnostic and treatment approaches for PAH. Expertise in the optimal management of PAH is uncommon with education and training lagging behind recent advances. Our needs assessment found pulmonologists, cardiologists, and critical care specialists have an opportunity to improve outcomes in patients with PAH by more accurately diagnosing and classifying PAH, by more consistently providing optimal treatment for PAH, and appropriately monitoring disease progression.

The goal of this continuing education activity is to enhance competency and build additional skills among pulmonologists, cardiologists, and critical care specialists in the management of PAH, ultimately improving symptoms, exercise tolerance, quality of life, and long-term outcomes in patients with PAH.

Program Developer/Facilitator


Target Audience

This activity is designed for pulmonologists, cardiologists, critical care practitioners and other medical professionals interested and involved in the treatment of patients with PAH.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Based on recent data presented at ATS 2012: Incorporate the use of appropriate tests to accurately diagnose and determine the disease severity classification for individual patients with PAH.
  2. Review emerging data presented at ATS 2012 that provides new insights into preferred treatment options for patients with Group 1 PAH.
  3. Review emerging data presented at ATS 2012 that provides new insights into preferred treatment options for patients with non-Group 1 PAH.
  4. Review recent data presented at ATS 2012 on clinical trials and emerging pharmacologic agents for treatment of PAH.


The University of Cincinnati is committed to offering CME programs that promote improvements or quality in healthcare. It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our sponsored educational programs. Faculty are required to disclose any real or apparent conflict(s) of interest related to the content of this CME activity. Disclosure of a relationship is not intended to suggest or condone bias, but is made to provide learners with information that may be of importance in their evaluation of the materials.

Dr. Waxman discloses that he is on the advisory board of United Therapeutics, Gilead Sciences, Pfizer; and a grant recipient of Gilead Sciences.

Dr. Chakninala discloses that he is on the advisory board of Actelion Pharmaceuticals, Gilead Sciences, United Therapeutics, and Novartis; a consultant to Actelion Pharmaceuticals, Gilead Sciences, United Therapeutics; on the speakers' bureau for Actelion Pharmaceuticals, Gilead Sciences, and United Therapeutics; and was a shareholder of Novartis (sold stock in 2011).

Dr. Tapson discloses that he is on the advisory board/consultant to Actelion Pharmaceuticals, Gilead Sciences, United Therapeutics, and Lung LCC; a grant recipient of Actelion Pharmaceuticals, United Therapeutics, Lung LCC, and Novartis; and on the speakers' bureau for Actelion Pharmaceuticals, Gilead Sciences, and United Therapeutics.

Planning Committee Disclosure Statement
These additional planning committee members have no financial relationships to disclose: Sara Thier, PHD, MPH; Susan P. Tyler, M.Ed, CMP, CCMEP; and Rick Ricer, MD.

Product Disclosure Information
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult the full prescribing information before using any product mentioned in the newsletter. When using drugs in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosage and uses of the drugs. Neither the publisher nor the sponsor promotes the use of any agent outside of approved labeling. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Credit Statements

This activity has been planned and implemented in accordance with the Essentials Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Cincinnati and MCM Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

University of Cincinnati designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

University of Cincinnati
Continuing Medical Education
3225 Eden Avenue, G24 Wherry Hall
Cincinnati, OH 45267
Phone: 513-558-7277

Commercial Support Statements

This activity is supported by an educational grant from Actelion Pharmaceuticals.


Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers

  1. Please turn off all pop-up blockers to assure access to the educational activity.
  2. Click on the "Start program" icon at the bottom of this page. If you are not already registered as a user of this website, this will bring you to the login/registration page where you will be able to register as a new member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
  3. The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. The activity will take approximately 60 minutes to complete.
  4. After the activity has finished, click on the "Post-test" button.
  5. Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen.

Certificate Fee



© 2012, MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, University of Cincinnati Office of CME, or Actelion Pharmaceuticals. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu